Key result
Pre-PCI Impella linked to ~34% lower short-term mortality vs during/post-PCI in AMI-CS.
Why the study?
Early Impella support before PCI may provide ventricular unloading and circulatory stabilization in AMI complicated by cardiogenic shock, but the optimal timing of implantation relative to PCI remains uncertain.
Does Impella implantation before PCI reduce short-term mortality (≤30 days) compared to implantation during or after PCI in adults with acute myocardial infarction complicated by cardiogenic shock?
Meta-Analysis (n=789)
Does Impella implantation before PCI reduce short-term mortality (≤30 days) compared to implantation during or after PCI in adults with acute myocardial infarction complicated by cardiogenic shock?
In patients with acute myocardial infarction and cardiogenic shock, implanting Impella prior to PCI is associated with a 34% relative reduction in short-term mortality and fewer vascular complications compared to implantation during or after PCI.
Answers are grounded in this paper and cite their sources.
Early Impella before PCI was associated with lower mortality in AMI-CS; leaves open need for randomized confirmation before practice change.
Background: AMI complicated by cardiogenic shock (AMI-CS) carries high early mortality despite rapid reperfusion. Reperfusion during severe hemodynamic instability may not adequately correct low cardiac output or end-organ hypoperfusion. Early Impella support before PCI may provide ventricular unloading and circulatory stabilization prior to revascularization; however, optimal implantation timing remains uncertain. Hypothesis: We hypothesized that Impella implantation before PCI would be associated with lower mortality and complication rates than implantation during or after PCI in patients with AMI-CS. Methods: We performed a PRISMA-guided systematic review and meta-analysis of MEDLINE/PubMed, Embase, Cochrane CENTRAL, Scopus, and Web of Science through February 2026. Eligible studies included adults with AMI-CS treated with Impella, reporting outcomes by timing: pre- or during/post-PCI. The primary outcome was short-term mortality (≤30 days). Secondary outcomes included major bleeding, limb ischemia, vascular complications, acute kidney injury (AKI), stroke, and device-related complications. Pooled risk ratios (RRs) with 95% CIs were calculated using random-effects models. Results: Seven studies (789 patients) were included; 320 received Impella pre-PCI and 469 during/post-PCI. Pre-PCI Impella was associated with significantly lower short-term mortality (36.3% vs. 53.1%; RR 0.66, 95% CI 0.55-0.80; p<0.0001; I 2 =12%) and fewer vascular complications (RR 0.62, 95% CI 0.41-0.92; p=0.02; I 2 =0%). No significant differences were observed in major bleeding (RR 0.52, 95% CI 0.23-1.19; p=0.12; I 2 =0%), limb ischemia (RR 0.91, 95% CI 0.60-1.39; p=0.67; I 2 =29%), AKI (RR 0.84, 95% CI 0.55-1.29; p=0.43; I 2 =23%), stroke (RR 0.70, 95% CI 0.09-5.25; p=0.73; I 2 =0%), or device-related complications (RR 0.91, 95% CI 0.60-1.39; p=0.67; I 2 =29%). Conclusions: In AMI-CS patients undergoing Impella-supported PCI, pre-PCI implantation was associated with lower short- and intermediate-term mortality than during/post-PCI implantation, without increased major bleeding, limb ischemia, or vascular complications, supporting early mechanical unloading and stabilization before revascularization.
No takes yet. Share an insight, caveat, or question.
Olanisa et al. (2026) conducted a meta-analysis in Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) (n=789). Impella implantation before PCI vs. Impella implantation during or after PCI was evaluated on Short-term mortality (≤30 days) (RR 0.66, 95% CI 0.55-0.80, p=<0.0001). Pre-PCI Impella implantation was associated with lower short-term mortality than during/post-PCI implantation in AMI-CS.
Synapse has enriched 10 related papers. Consider them for comparative context: